The U.S. Food and Drug Administration approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the ...
The FDA recently granted Fast Track designation to Assembly Biosciences, Inc’s novel treatment for patients with chronic hepatitis B virus (HBV) infection. The drug, ABI-H0731, is the manufacturer’s lead oral HBV core inhibitor, according to a press release.
The US Food and Drug Administration (FDA) and the European Medicines Agency's (EMA) are recommending new safety precautions for ViiV Healthcare's HIV drug dolutegravir.
FDA Approves Ortho Clinical Diagnostics VITROS® Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator on the VITROS® 3600 Immunodiagnostic System
VITROS HIV Combo, a fourth-generation test, detects both HIV-1 and HIV-2 antibodies (Ab) and the p24 antigen (Ag), enabling HIV-1 acute infection detection earlier than third-generation tests.
FDA approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1).